| Dr Bricia O Toro De Zarei, MD | |
|
1200 Calle Milagros, Brownsville, TX 78526-3354 | |
| (956) 350-2508 | |
| (956) 350-2509 |
| Full Name | Dr Bricia O Toro De Zarei |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 30 Years |
| Location | 1200 Calle Milagros, Brownsville, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124026299 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | L5156 (Texas) | Primary |
| Entity Name | Bricia Toro De Zarei M.d. P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467409425 PECOS PAC ID: 1658396031 Enrollment ID: O20051014000238 |
News Archive
OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.
Enzon Pharmaceuticals, Inc. today announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013. As a result of the sale of the specialty pharmaceutical business on January 29, 2010, the Company was required to offer to repurchase for cash any and all of its convertible notes at face value. This offer expired on March 5, 2010 and no notes were tendered.
Researchers survey hygiene procedures in food supply chains implemented during the COVID-19 pandemic.
With a desire to inhibit metastasis, Cornell biomedical engineers have found the natural switch between the body's inflammatory response and how malignant breast cancer cells use the bloodstream to spread.
Although still rare, the incidence of thyroid cancer is increasing. In this longitudinal study over 12 years from a large cancer registry, Kent and colleagues used the Ontario Cancer Registry to identify 7422 cases of differentiated thyroid cancer from 1990 to 2001.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bricia O Toro De Zarei, MD 1200 Calle Milagros, Brownsville, TX 78526-3354 Ph: (956) 350-2508 | Dr Bricia O Toro De Zarei, MD 1200 Calle Milagros, Brownsville, TX 78526-3354 Ph: (956) 350-2508 |
News Archive
OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.
Enzon Pharmaceuticals, Inc. today announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013. As a result of the sale of the specialty pharmaceutical business on January 29, 2010, the Company was required to offer to repurchase for cash any and all of its convertible notes at face value. This offer expired on March 5, 2010 and no notes were tendered.
Researchers survey hygiene procedures in food supply chains implemented during the COVID-19 pandemic.
With a desire to inhibit metastasis, Cornell biomedical engineers have found the natural switch between the body's inflammatory response and how malignant breast cancer cells use the bloodstream to spread.
Although still rare, the incidence of thyroid cancer is increasing. In this longitudinal study over 12 years from a large cancer registry, Kent and colleagues used the Ontario Cancer Registry to identify 7422 cases of differentiated thyroid cancer from 1990 to 2001.
› Verified 3 days ago
Ammar Mohamed-ali Halloum, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 844 Central Blvd, 420, Brownsville, TX 78520 Phone: 956-428-7862 Fax: 956-440-0395 | |
Syed Azhar Hassan, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3761 Ruben M Torres Sr Blvd, Brownsville, TX 78526 Phone: 956-230-4971 Fax: 956-230-4972 | |
Dr. Jose Luis Villalobos Jr., MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4970 N Expressway Ste B, Brownsville, TX 78526 Phone: 956-609-4430 Fax: 956-446-9902 | |
Juan Diego Gonzalez, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3125 W Alton Gloor Blvd, Brownsville, TX 78520 Phone: 956-544-5700 Fax: 956-350-9573 | |
Ricardo Martin Schwarcz, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 844 Central Blvd, Suite 420, Brownsville, TX 78520 Phone: 956-542-9900 Fax: 956-574-0003 | |
Darlington Udeh, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 110 Uptown Ave Ste B, Brownsville, TX 78520 Phone: 956-525-7817 Fax: 956-525-7800 |